Sensei Biotherapeutics (NASDAQ:SNSE) Upgraded to Buy by Zacks Investment Research

Sensei Biotherapeutics (NASDAQ:SNSE – Get Rating) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report issued on Tuesday, Zacks.com reports. The firm presently has a $1.75 price objective on the stock. Zacks Investment Research‘s price target would suggest a potential upside of 5.42% from the company’s previous close.

According to Zacks, “Sensei Biotherapeutics Inc. is a clinical-stage immunotherapy company. It is focused on the discovery and development of therapeutics for cancer. The company’s product pipeline includes SNS-301, SNS-401 and SNS-VISTA. Sensei Biotherapeutics Inc. is based in BOSTON, Md. “

Separately, Piper Sandler lowered their price objective on Sensei Biotherapeutics from $12.00 to $10.00 and set an “overweight” rating for the company in a research note on Thursday, March 10th. Two equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat.com, Sensei Biotherapeutics currently has an average rating of “Buy” and an average price target of $10.96.

Shares of SNSE stock traded up $0.06 during trading hours on Tuesday, reaching $1.66. The company had a trading volume of 4,205 shares, compared to its average volume of 94,724. The company has a debt-to-equity ratio of 0.01, a quick ratio of 18.27 and a current ratio of 18.27. Sensei Biotherapeutics has a twelve month low of $1.45 and a twelve month high of $15.12. The company has a market capitalization of $50.85 million, a P/E ratio of -1.25 and a beta of 0.79. The stock’s fifty day simple moving average is $2.10 and its 200 day simple moving average is $4.51.

Sensei Biotherapeutics (NASDAQ:SNSE – Get Rating) last posted its earnings results on Tuesday, May 10th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.05). As a group, equities analysts expect that Sensei Biotherapeutics will post -1.64 earnings per share for the current year.

In other news, major shareholder Cambrian Biopharma Inc bought 15,000 shares of Sensei Biotherapeutics stock in a transaction on Friday, February 18th. The shares were bought at an average price of $3.97 per share, with a total value of $59,550.00. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In the last ninety days, insiders have acquired 43,703 shares of company stock worth $167,829.

A number of large investors have recently added to or reduced their stakes in SNSE. Royal Bank of Canada lifted its holdings in Sensei Biotherapeutics by 255.1% during the 3rd quarter. Royal Bank of Canada now owns 2,411 shares of the company’s stock worth $25,000 after buying an additional 1,732 shares during the last quarter. Citigroup Inc. lifted its holdings in shares of Sensei Biotherapeutics by 565.5% in the 3rd quarter. Citigroup Inc. now owns 2,409 shares of the company’s stock worth $25,000 after purchasing an additional 2,047 shares during the last quarter. Raymond James & Associates bought a new stake in shares of Sensei Biotherapeutics in the 1st quarter worth approximately $30,000. Leo Brokerage LLC bought a new stake in shares of Sensei Biotherapeutics in the 1st quarter worth approximately $34,000. Finally, Wells Fargo & Company MN lifted its holdings in shares of Sensei Biotherapeutics by 14,298.4% in the 4th quarter. Wells Fargo & Company MN now owns 8,783 shares of the company’s stock worth $51,000 after purchasing an additional 8,722 shares during the last quarter. 11.10% of the stock is currently owned by institutional investors.

Sensei Biotherapeutics Company Profile (Get Rating)

Sensei Biotherapeutics, Inc, a biopharmaceutical company, engages in the discovery and development of immunotherapies with an initial focus on treatments for cancer. It develops proprietary ImmunoPhage platform, an immunotherapy approach that is designed to utilize bacteriophage to induce a focused and coordinated innate and adaptive immune response; and Tumor Microenvironment Activated Biologics, a platform designed to unleash the anti-tumor potential of T-cells, as well as human monoclonal antibodies that are selectively active in the tumor microenvironment and target immune checkpoints or other critical immune pathways.

Further Reading